IKKβ inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury

Nancy C. Moss, William E. Stansfield, Monte Willis, Ru Hang Tang, Craig H. Selzman

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Despite years of experimental and clinical research, myocardial ischemia-reperfusion (IR) remains an important cause of cardiac morbidity and mortality. The transcription factor nuclear factor-κB (NF-κB) has been implicated as a key mediator of reperfusion injury. Activation of NF-κB is dependent upon the phosphorylation of its inhibitor, IκBα, by the specific inhibitory κB kinase (IKK) subunit, IKKβ. We hypothesized that specific antagonism of the NF-κB inflammatory pathway through IKKβ inhibition reduces acute myocardial damage following IR injury. C57BL/6 mice underwent left anterior descending (LAD) artery ligation and release in an experimental model of acute IR. Bay 65-1942, an ATP-competitive inhibitor that selectively targets IKKβ kinase activity, was administered intraperitoneally either prior to ischemia, at reperfusion, or 2 h after reperfusion. Compared with untreated animals, mice treated with IKKβ inhibition had significant reduction in left ventricular infarct size. Cardiac function was also preserved following pretreatment with IKKβ inhibition. These findings were further associated with decreased expression of phosphorylated IκBα and phosphorylated p65 in myocardial tissue. In addition, IKKβ inhibition decreased serum levels of TNF-α and IL-6, two prototypical downstream effectors of NF-κB activity. These results demonstrate that specific IKKβ inhibition can provide both acute and delayed cardioprotection and offers a clinically accessible target for preventing cardiac injury following IR.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume293
Issue number4
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Reperfusion Injury
Reperfusion
Wounds and Injuries
Phosphotransferases
Ischemia
Myocardial Reperfusion
Inbred C57BL Mouse
Myocardial Ischemia
Ligation
Interleukin-6
Transcription Factors
Theoretical Models
Arteries
Adenosine Triphosphate
Phosphorylation
Morbidity
Mortality
Serum
Research

Keywords

  • Inhibitory κB kinase-β
  • Myocardial infarction
  • Nuclear factor-κB

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

IKKβ inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. / Moss, Nancy C.; Stansfield, William E.; Willis, Monte; Tang, Ru Hang; Selzman, Craig H.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 293, No. 4, 01.10.2007.

Research output: Contribution to journalArticle

@article{a251768311c249f686ba3a1bc7724696,
title = "IKKβ inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury",
abstract = "Despite years of experimental and clinical research, myocardial ischemia-reperfusion (IR) remains an important cause of cardiac morbidity and mortality. The transcription factor nuclear factor-κB (NF-κB) has been implicated as a key mediator of reperfusion injury. Activation of NF-κB is dependent upon the phosphorylation of its inhibitor, IκBα, by the specific inhibitory κB kinase (IKK) subunit, IKKβ. We hypothesized that specific antagonism of the NF-κB inflammatory pathway through IKKβ inhibition reduces acute myocardial damage following IR injury. C57BL/6 mice underwent left anterior descending (LAD) artery ligation and release in an experimental model of acute IR. Bay 65-1942, an ATP-competitive inhibitor that selectively targets IKKβ kinase activity, was administered intraperitoneally either prior to ischemia, at reperfusion, or 2 h after reperfusion. Compared with untreated animals, mice treated with IKKβ inhibition had significant reduction in left ventricular infarct size. Cardiac function was also preserved following pretreatment with IKKβ inhibition. These findings were further associated with decreased expression of phosphorylated IκBα and phosphorylated p65 in myocardial tissue. In addition, IKKβ inhibition decreased serum levels of TNF-α and IL-6, two prototypical downstream effectors of NF-κB activity. These results demonstrate that specific IKKβ inhibition can provide both acute and delayed cardioprotection and offers a clinically accessible target for preventing cardiac injury following IR.",
keywords = "Inhibitory κB kinase-β, Myocardial infarction, Nuclear factor-κB",
author = "Moss, {Nancy C.} and Stansfield, {William E.} and Monte Willis and Tang, {Ru Hang} and Selzman, {Craig H.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1152/ajpheart.00776.2007",
language = "English (US)",
volume = "293",
journal = "American Journal of Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - IKKβ inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury

AU - Moss, Nancy C.

AU - Stansfield, William E.

AU - Willis, Monte

AU - Tang, Ru Hang

AU - Selzman, Craig H.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Despite years of experimental and clinical research, myocardial ischemia-reperfusion (IR) remains an important cause of cardiac morbidity and mortality. The transcription factor nuclear factor-κB (NF-κB) has been implicated as a key mediator of reperfusion injury. Activation of NF-κB is dependent upon the phosphorylation of its inhibitor, IκBα, by the specific inhibitory κB kinase (IKK) subunit, IKKβ. We hypothesized that specific antagonism of the NF-κB inflammatory pathway through IKKβ inhibition reduces acute myocardial damage following IR injury. C57BL/6 mice underwent left anterior descending (LAD) artery ligation and release in an experimental model of acute IR. Bay 65-1942, an ATP-competitive inhibitor that selectively targets IKKβ kinase activity, was administered intraperitoneally either prior to ischemia, at reperfusion, or 2 h after reperfusion. Compared with untreated animals, mice treated with IKKβ inhibition had significant reduction in left ventricular infarct size. Cardiac function was also preserved following pretreatment with IKKβ inhibition. These findings were further associated with decreased expression of phosphorylated IκBα and phosphorylated p65 in myocardial tissue. In addition, IKKβ inhibition decreased serum levels of TNF-α and IL-6, two prototypical downstream effectors of NF-κB activity. These results demonstrate that specific IKKβ inhibition can provide both acute and delayed cardioprotection and offers a clinically accessible target for preventing cardiac injury following IR.

AB - Despite years of experimental and clinical research, myocardial ischemia-reperfusion (IR) remains an important cause of cardiac morbidity and mortality. The transcription factor nuclear factor-κB (NF-κB) has been implicated as a key mediator of reperfusion injury. Activation of NF-κB is dependent upon the phosphorylation of its inhibitor, IκBα, by the specific inhibitory κB kinase (IKK) subunit, IKKβ. We hypothesized that specific antagonism of the NF-κB inflammatory pathway through IKKβ inhibition reduces acute myocardial damage following IR injury. C57BL/6 mice underwent left anterior descending (LAD) artery ligation and release in an experimental model of acute IR. Bay 65-1942, an ATP-competitive inhibitor that selectively targets IKKβ kinase activity, was administered intraperitoneally either prior to ischemia, at reperfusion, or 2 h after reperfusion. Compared with untreated animals, mice treated with IKKβ inhibition had significant reduction in left ventricular infarct size. Cardiac function was also preserved following pretreatment with IKKβ inhibition. These findings were further associated with decreased expression of phosphorylated IκBα and phosphorylated p65 in myocardial tissue. In addition, IKKβ inhibition decreased serum levels of TNF-α and IL-6, two prototypical downstream effectors of NF-κB activity. These results demonstrate that specific IKKβ inhibition can provide both acute and delayed cardioprotection and offers a clinically accessible target for preventing cardiac injury following IR.

KW - Inhibitory κB kinase-β

KW - Myocardial infarction

KW - Nuclear factor-κB

UR - http://www.scopus.com/inward/record.url?scp=35348970307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348970307&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00776.2007

DO - 10.1152/ajpheart.00776.2007

M3 - Article

VL - 293

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6135

IS - 4

ER -